• 中国中文核心期刊
  • 中国科学引文数据库核心期刊
  • 中国科技核心期刊
  • 中国高校百佳科技期刊
高级检索

英国罕见病用药纳入报销体系的主要途径及对我国的启示

袁妮, 田婷婷, 张海军, 王勇

袁妮, 田婷婷, 张海军, 王勇. 英国罕见病用药纳入报销体系的主要途径及对我国的启示[J]. 中国药科大学学报, 2019, 50(1): 113-119. DOI: 10.11665/j.issn.1000-5048.20190116
引用本文: 袁妮, 田婷婷, 张海军, 王勇. 英国罕见病用药纳入报销体系的主要途径及对我国的启示[J]. 中国药科大学学报, 2019, 50(1): 113-119. DOI: 10.11665/j.issn.1000-5048.20190116
shu
YUAN Ni, TIAN Tingting, ZHANG Haijun, WANG Yong. Major routes for orphan drugs to be incorporated into the reimbursement system of UK and the enlightenment to China[J]. Journal of China Pharmaceutical University, 2019, 50(1): 113-119. DOI: 10.11665/j.issn.1000-5048.20190116
Citation: YUAN Ni, TIAN Tingting, ZHANG Haijun, WANG Yong. Major routes for orphan drugs to be incorporated into the reimbursement system of UK and the enlightenment to China[J]. Journal of China Pharmaceutical University, 2019, 50(1): 113-119. DOI: 10.11665/j.issn.1000-5048.20190116
shu

英国罕见病用药纳入报销体系的主要途径及对我国的启示

  • 1.

    中国药科大学国际医药商学院

  • 2.

    大连医科大学公共卫生学院

Major routes for orphan drugs to be incorporated into the reimbursement system of UK and the enlightenment to China

摘要

    摘要
  • 摘要: 为我国建立合理且多元化的罕见病用药纳入报销体系制度提供经验及启示，本研究通过查阅英国国家卫生与临床优化研究所(National Institute for Health and Care Excellence，NICE)与英国国民健康保障体系(National Health Service，NHS)官网，收集英国有关罕见病用药纳入报销体系的资料，归纳并分析相关文献，对罕见病患者药品的可及性进行理论研究。在NHS体系中，英国罕见病用药纳入报销体系主要可以通过7种途径:由NICE负责评估的3种途径(多技术评估MTA、单一技术评估STA、高度专业化技术评估HST)与NHS直接管理的4种途径(专项购买服务、肿瘤药物基金CDF、个人资金申请IFRs、对缺乏临床数据项目的评估购买计划CtE)。通过分析英国罕见病用药纳入报销体系的7种主要途径及英国在实施多种纳入报销途径中出现的问题，对我国罕见病用药的报销制度的建立有一定借鉴意义。
    Abstract: In order to provide enlightening experience for the establishment of reasonable and diversified orphan drugs into the reimbursement system in China, the official websites of the National Institute for Health and Care Excellence(NICE)and the National Health Service(NHS)in the UK were inspected, collecting and summarizing the relevant documents, on the inclusion of orphan drugs into the reimbursement system. Relevant literatures were analyzed with theoretical studies on the accessibility of medicines for patients with rare diseases. In the NHS system, the inclusion of orphan drugs into the reimbursement system in the UK can be achieved mainly through seven routes, with three routes that are evaluated by NICE(MTA, STA and HST)and four are directly managed by the NHS(specialized commissioning, CDF, IFRs, CtE). Through the analysis of the inclusion of orphan drugs into the reimbursement system and the various problems in the UK, we have found some enlightening experience for the establishment of the reimbursement system for orphan drugs in China.
    • HTML全文
    • 参考文献(17)
  • [1] Gong SW.Study of management strategies of improving access to orphan drugs in china(促进我国罕见病患者药品可及性的管理策略研究)[D].Wuhan:Huazhong University of Science and Technology,2008.
    [2] Sui BY,Qi XR.Experience from translation mechanisms in the NICE health technology assessment to NHS decision making[J].Chin J Health Policy(中国卫生政策研究),2015,8(7):74-78.
    [3] National Institute for Health and Care Excellence.Guide to the processes of technology appraisal2014[R].London:NICE,2014.
    [4] National Institute for Health and Care Excellence.Summary of decisions[EB/OL].[2018-03-19] .https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice technology-appraisal-guidance/summary-of-decisions.
    [5] National Institute for Health and Care Excellence.Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease[R].London:NICE,2017.
    [6] National Institute for Health and Care Excellence.Summary of decisions[EB/OL].[2018-05-17] .https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-technology-appraisal-guidance/summary-of-decisions.
    [7] National Institute for Health and Care Excellence.Guide to the processes of technology appraisal 2014[R].London:NICE,2014.
    [8] National Institute for Health and Care Excellence.Eltrombopag for treating chronic immune(idiopathic)thrombocytopenic purpura[R].London:NICE,2013.
    [9] National Institute for Health and Care Excellence.Interim process and methods of the highly specialized technologies programme[R].London:NICE,2017.
    [10] National Health Service.Specialized services[EB/OL].[2018-05-18] .https://www.england.nhs.uk/commissioning/spec-services/.
    [11] NHS England.Implementation plan for the uk strategy for rare diseases[R].England:NHS England,2018.
    [12] NHS England Cancer Drugs Fund Team.Appraisal and funding of cancer drugs from July 2016(including the new Cancer Drugs Fund)- A new deal for patients,taxpayers and industry[R].England:NHS England,2016.
    [13] NHS England Cancer Drugs Fund Team.National cancer drugs fund list[R].England:NHS England,2016.
    [14] National Institute for Health and Care Excellence.Consultation comments on the draft remit and draft scope for the technology appraisal of cabozantinib for previously treated advanced renal cell carcinoma[R].England:NICE.
    [15] Specialized Commissioning Team.Standard operating procedures:individual funding requests[R].England:NHS England,2017.
    [16] NHS England.Methods:Commissioning through Evaluation[R].England:NHS England,2017.
    [17] National Health Service.Commissioning through evaluation[EB/OL].[2018-05-20] .https://www.england.nhs.uk/commissioning/spec-services/npc-crg/comm-eval/.
    • 相关文章
    • 施引文献(14)

  • 期刊类型引用(13)

    1. 燕传勇，郑佳，马璐瑶，郗存显，郭思言，张文华，母昭德. 超高效液相色谱-四极杆/静电场轨道阱高分辨质谱法建立97种化学药物的质谱数据库并定性分析保健品中的化学药物. 理化检验-化学分册. 2024(11): 1173-1182 . 百度学术
    2. 刘杰. 保健食品中微量元素的测定. 农产品加工. 2023(01): 54-56+59 . 百度学术
    3. 朱松松，李贝贝，吴婉琴，夏金涛，江丰，王会霞. ASSURE-NMR-HSQC实验检测保健食品中西地那非类物质. 化学研究与应用. 2023(06): 1487-1492 . 百度学术
    4. 范春蕾，陈达杰，陈倩倩，徐柳彬，王园，倪梅林，湛嘉，朱海强. 植物源性保健食品中60种非法添加物同时测定方法研究. 中国口岸科学技术. 2023(07): 39-46 . 百度学术
    5. 杨明明，郑佳，马璐瑶，郗存显，郭思言，张文华，母昭德. UHPLC/MS/MS快速筛查保健食品中13种激素和11种降血糖化学药物. 广州化工. 2023(13): 118-123 . 百度学术
    6. 郭茜茜，吴鹏，刘志洋，赵凌侠，杨慧. UPLC同时测定辣椒胎座中辣椒素和二氢辣椒素. 东北农业科学. 2023(06): 141-144 . 百度学术
    7. 贺志乔，吴树栋，朱富强，高翠. 保健食品中喹诺酮类药物常压质谱快速检测法. 食品工业. 2022(08): 304-308 . 百度学术
    8. 胡晓楠，徐慧静，李莹，郭文丽，纪卫红，王欣. 高效液相色谱-串联质谱法检测保健食品中25种非甾体类抗炎药. 食品安全质量检测学报. 2022(19): 6409-6415 . 百度学术
    9. 陈明曦，李艳梅，孙婷，于治国，王东凯. 液相色谱-质谱联用技术在中药质量研究中的应用. 中国药剂学杂志. 2021(01): 12-17 . 百度学术
    10. 吴蕾，吴昊，张莉，许世富，刘红云，蔡一杰，许晓靖. 超高效液相色谱-四极杆飞行时间质谱法快速测定混合型饲料添加剂中14种化学药物. 食品安全质量检测学报. 2021(08): 3104-3112 . 百度学术
    11. 焦奥南，王程程，莫颖宁. 基于SWOT-PEST分析的我国中药类保健食品市场发展研究. 食品与药品. 2021(05): 438-444 . 百度学术
    12. 冯梦雨，刘栓，高燕，周澍堃，国振，李秀琴，张庆合. 玉米赤霉酮纯度标准物质杂质定性鉴定与主成分定量分析. 色谱. 2019(08): 911-917 . 百度学术
    13. 谭攀，吴鑫，蔡杜曼，胡金梅. 酚酞单克隆抗体的制备. 食品安全质量检测学报. 2019(24): 8479-8483 . 百度学术

    其他类型引用(1)

    • 资源附件(0)
计量
  • 文章访问数:  844
  • HTML全文浏览量:  7
  • PDF下载量:  1563
  • 被引次数: 14
出版历程
  • 刊出日期:  2019-02-24

目录

摘要
HTML全文
    参考文献(17)
    相关文章
    施引文献(14)
    资源附件(0)

    /

    返回文章
    返回

    版权所有：《中国药科大学学报》编辑部苏ICP备05007142号

    地址：江苏省南京市鼓楼区童家巷24号（210009）电话: 025-83271566E-mail: xuebao@cpu.edu.cn

    本系统由 北京仁和汇智信息技术有限公司 开发  百度统计

    访问量：400534

    x 关闭 永久关闭